Literature DB >> 21422219

Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

A Espinel-Ingroff1, A Fothergill, J Fuller, E Johnson, T Pelaez, J Turnidge.   

Abstract

Clinical breakpoints have not been established for mold testing. Epidemiologic cutoff values (ECVs) are available for six Aspergillus spp. and the triazoles, but not for caspofungin. Wild-type (WT) minimal effective concentration (MEC) distributions (organisms in a species-drug combination with no acquired resistance mechanisms) were defined in order to establish ECVs for six Aspergillus spp. and caspofungin. The number of available isolates was as follows: 1,691 A. fumigatus, 432 A. flavus, 192 A. nidulans, 440 A. niger, 385 A. terreus, and 75 A. versicolor isolates. CLSI broth microdilution MEC data gathered in five independent laboratories in Canada, Europe, and the United States were aggregated for the analyses. ECVs expressed in μg/ml that captured 95% and 99% of the modeled wild-type population were for A. fumigatus 0.5 and 1, A. flavus 0.25 and 0.5, A. nidulans 0.5 and 0.5, A. niger 0.25 and 0.25, A. terreus 0.25 and 0.5, and A. versicolor 0.25 and 0.5. Although caspofungin ECVs are not designed to predict the outcome of therapy, they may aid in the detection of strains with reduced antifungal susceptibility to this agent and acquired resistance mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21422219      PMCID: PMC3101428          DOI: 10.1128/AAC.01730-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus.

Authors:  Eleusa Maria F Rocha; Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

3.  Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.

Authors:  John D Cleary; Guillermo Garcia-Effron; Stanley W Chapman; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

4.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

5.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Authors:  George R Thompson; Nathan P Wiederhold; Ana C Vallor; Nyria C Villareal; James S Lewis; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

7.  Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.

Authors:  Adrienne Madureira; Anne Bergeron; Claire Lacroix; Marie Robin; Vanderson Rocha; Régis Peffault de Latour; Christèle Ferry; Agnès Devergie; Jordane Lapalu; Eliane Gluckmana; Gérard Socié; Mahmoud Ghannoum; Patricia Ribaud
Journal:  Int J Antimicrob Agents       Date:  2007-12       Impact factor: 5.283

8.  Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.

Authors:  Marie Desnos-Ollivier; Stéphane Bretagne; Dorothée Raoux; Damien Hoinard; Françoise Dromer; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

9.  Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.

Authors:  Maiken Cavling Arendrup; Susanne Perkhofer; Susan J Howard; Guillermo Garcia-Effron; Aimanianda Vishukumar; David Perlin; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

10.  Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report.

Authors:  S Eschertzhuber; C Velik-Salchner; C Hoermann; D Hoefer; C Lass-Florl
Journal:  Transpl Infect Dis       Date:  2007-07-01       Impact factor: 2.228

View more
  43 in total

1.  Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species.

Authors:  Elena De Carolis; Antonietta Vella; Ada R Florio; Patrizia Posteraro; David S Perlin; Maurizio Sanguinetti; Brunella Posteraro
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

Review 2.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates.

Authors:  Mojtaba Taghizadeh-Armaki; Mohammad Taghi Hedayati; Saham Ansari; Saeed Mahdavi Omran; Sasan Saber; Haleh Rafati; Jan Zoll; Henrich A van der Lee; Willem J G Melchers; Paul E Verweij; Seyedmojtaba Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 4.  The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases.

Authors:  Ilan S Schwartz; Thomas F Patterson
Journal:  Curr Infect Dis Rep       Date:  2018-02-05       Impact factor: 3.725

Review 5.  Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard.

Authors:  Shawn R Lockhart; Mahmoud A Ghannoum; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2017-02-15       Impact factor: 5.948

6.  Evaluation of Etest performed in Mueller-Hinton agar supplemented with glucose for antifungal susceptibility testing of clinical isolates of filamentous fungi.

Authors:  E Pinto; M Lago; L Branco; L A Vale-Silva; M D Pinheiro
Journal:  Mycopathologia       Date:  2014-02-26       Impact factor: 2.574

7.  Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species.

Authors:  Joseph Meletiadis; Maria Siopi; Lamprini Kanioura; Karin Meinike Jørgensen; David S Perlin; Johan W Mouton; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

8.  In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.

Authors:  Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

9.  Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.

Authors:  A Espinel-Ingroff; M Alvarez-Fernandez; E Cantón; P L Carver; S C-A Chen; G Eschenauer; D L Getsinger; G M Gonzalez; N P Govender; A Grancini; K E Hanson; S E Kidd; K Klinker; C J Kubin; J V Kus; S R Lockhart; J Meletiadis; A J Morris; T Pelaez; G Quindós; M Rodriguez-Iglesias; F Sánchez-Reus; S Shoham; N L Wengenack; N Borrell Solé; J Echeverria; J Esperalba; E Gómez-G de la Pedrosa; I García García; M J Linares; F Marco; P Merino; J Pemán; L Pérez Del Molino; E Roselló Mayans; C Rubio Calvo; M Ruiz Pérez de Pipaon; G Yagüe; G Garcia-Effron; J Guinea; D S Perlin; M Sanguinetti; R Shields; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

10.  Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.

Authors:  A Espinel-Ingroff; A Chowdhary; G M Gonzalez; C Lass-Flörl; E Martin-Mazuelos; J Meis; T Peláez; M A Pfaller; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.